Back

Risk prediction model for early left ventricular systolic dysfunction in breast cancer patients when the global longitudinal strain is not available

12 December 2025 (11:30 - 12:15)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: what are the new imaging insights? Systolic and Diastolic Function EACVI Premium Access EACVI 2025 European Association of Cardiovascular Imaging (EACVI)

About the speaker

Photo
Doctor Angelina Stevanovic

Belgrade (Serbia)

6 More presentations in this session

Presentation thumbnail
Under pressure: right ventricular and right atrial strain predict in-hospital death in cancer patients with pulmonary embolism
Doctor A. Vijiiac (Bucharest, RO)
Abstract Slides
Presentation thumbnail
Predictive value of global longitudinal strain (GLS) in breast cancer patients undergoing trastuzumab-based chemotherapy
Doctor V. Dimitrova (Sofia, BG)
Abstract Slides
Presentation thumbnail
Assessing cancer therapy-related cardiac dysfunction risk in non-Hodgkin lymphoma patients, the role of comprehensive echocardiographic monitoring
Doctor D. Bursacovschi (Chisinau, MD)
Abstract Slides
Presentation thumbnail
Right ventricular dysfunction and mortality in breast cancer patients treated with anthracyclines: a retrospective cohort study
Doctor N. Sari (Jakarta, ID)
Abstract Slides
Presentation thumbnail
Semaglutide preserves myocardial function in a murine model of sequential anthracycline trastuzumab induced early cardiotoxicity: insights from speckle tracking echocardiography
Doctor N. Maurea (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology: what are the new imaging insights?

The Event

Event poster

EACVI 2025

12 December 2025 11:30 CET
You may be interested in
thumbnail
Congress Session
Recent advances in clinical practice guidelines: what the imager needs to know and apply - Part 2
thumbnail
Congress Presentation
Diastolic function and left atrial pressures
thumbnail
Congress Presentation
Threshold values for diastolic dysfunction parameters indicative of increased mortality risk in a real-world patient cohort

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources